Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$35.09 USD
-1.90 (-5.14%)
Updated Aug 9, 2024 04:00 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Brokerage Reports
Longboard Pharmaceuticals, Inc. [LBPH]
Reports for Purchase
Showing records 1 - 20 ( 65 total )
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Prescription Sales Tracker: Neurology, Nephrology, GI, Cardiology
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Prescription Sales Tracker: Neurology, Nephrology, GI, Cardiology
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Prescription Sales Tracker: Neurology, Nephrology, GI, Cardiology
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 OLE Data Support Durability of Treatment With Lead Epilepsy Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Prescription Sales Tracker: Neurology, Nephrology, GI, Cardiology
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Prescription Sales Tracker: Neurology, Nephrology, GI, Cardiology
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Lead Epilepsy Program Expected to Initiate Phase 3 by Year-End 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Digging In Deeper To PACIFIC Data -- Detailed Results Presented
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
AAN Takeaway: Full PACIFIC Dataset Supports Advancement of Bexicaserin to Phase 3 in Epilepsy by End-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Lead Bexicaserin Phase 3 Program in Epilepsy to Start by End-2024; 4Q23 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Moving Full Speed Ahead Toward Pivotal Phase 3 Program on Potential Blockbuster Bexicaserin in Epilepsy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Robust Phase 2 Data in Lead Epilepsy Program Support Advancement to Phase 3; Raising Price Target to $60; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Catching A Good Wave With PACIFIC Data - Layering In The Offering
Provider: Wedbush Securities Inc.
Analyst: CHICO L